About BenevolentAI

BenevolentAI is a clinical-stage company that applies advanced artificial intelligence to accelerate drug discovery. The company has built a proprietary platform combining a decade of investment in knowledge graphs and machine learning with wet-lab capabilities, enabling pharmaceutical collaborations and an in-house pipeline of over 20 drug programmes. The platform targets the complex decisions that drive pharmaceutical R&D, giving scientists and executives access to life science intelligence for more confident drug development. Despite billions spent annually, drug development fails over 90% of the time, and BenevolentAI aims to change this through genuine collaboration between science and technology teams.